Drugs from overseas to get on fast track
“China has great pharmaceutical production capacity, so it can provide support to the health of the people in BRICS nations and other countries,” he said.
BRICS comprises Brazil, Russia, India, China and South Africa.
The administration has adopted a series of reform measures on the review and approval of new drugs to accelerate approvals and meet the needs of domestic patients in recent years, Wu said.
The authorities will encourage medical institutions to give priority to new drugs that have proved effective and are reasonably priced, and support the inclusion of such new drugs in the list of drugs whose cost can be reimbursed by basic medical insurance programs, according to a draft regulation released by the administration in May.
Certain types of drugs and medical equipment already in use in other countries, such as those for curing rare diseases, can also gain priority approval for sale in the domestic market, the draft said.
As of the end of June, the administration had established routine work relations with drug regulatory authorities in 66 countries, and signed 42 agreements for bilateral cooperation with 28 countries and regions, said Yuan Lin, chief of the administration’s international cooperation department.